At Capsugel, we are devoted to developing capsules and other solutions to support our customers most difficult dosing challenges.
At Capsugel, we are driven by our focus on quality and have implemented numerous process quality initiatives to continuously improve the overall quality of our products.
At Capsugel, we are committed to ensuring an unmatched certainty of supply for our customers - and since you span the globe, so do we, with multiple production and business facilities worldwide.
World Class People
At Capsugel, we are focused on bringing and keeping top talent in our organization - it's our way of making sure you have the high-quality capsules you need, when and where you need them.
World Class People
At Capsugel, we are motivated by seeing our customers satisfied - so we keep your needs at the center of all our decisions to help make your job easier.
At Capsugel, we are dedicated to creating value for both our customers and their customers while always striving to provide investors with superior returns.
Capsugel and Cardax to Collaborate on Development of Proprietary Astaxanthin Products
Morristown, N.J. and Honolulu, Hawaii, August 19, 2014 – Capsugel and Cardax, Inc. (“Cardax”) (OTCQB: CDXI) announced today a collaboration to develop unique astaxanthin products for the consumer health market. The goal of the collaboration is to commercialize proprietary formulations of nature-identical synthetic astaxanthin products with pharmaceutical-grade purity that will provide improved oral bioavailability compared with other astaxanthin products on the market. Astaxanthin is currently used as a specialized antioxidant.
Study Confirms Suitability Of Capsugel’s Hard Capsules in QbD Pharmaceutical Product Development and Manufacturing
Morristown, NJ – July 28, 2014 – Capsugel recently published a study in AAPS’ PharmSciTech journal confirming that Capsugel capsules are suitable excipients for Quality by Design (QbD)-based product development and manufacturing. The study examined the Critical Quality Attributes (CQA) within, and between, different batches of empty hard capsules to better understand these variabilities and their impact on the desired quality and performance of the final dosage form. The results provide the first comprehensive collection of relevant QbD data for hard capsules, which researchers can use to design capsule product development programs that adhere to the QbD principles for modern pharmaceutics.
Bend Research is now part of Capsugel's Dosage Form Solutions (DFS) business. Bend Research brings expertise in novel formulations, including spray-dried dispersions and hot-melt extrusion, as well as technologies in the areas of controlled-release, inhalation and bio-therapeutics. These capabilities complement Capsugel DFS’ premier capabilities in lipid and liquid formulations, modified and targeted release delivery and specialized manufacturing solutions.
Encap Drug Delivery
Based in Scotland, Encap’s focus on liquid and semi-solid encapsulation-based product development, and clinical and commercial manufacturing for the pharmaceutical industry, complements Capsugel’s recently-established Dosage Form Solutions (DFS) business unit which develops and manufactures innovative products for the healthcare industry.